INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Seneca Biopharma, Inc. for Potential Securities Violations and Breach of Fiduciary Duty Claims
February 13, 2020 12:50 ET
|
Fields Kupka & Shukurov LLP
NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Fields Kupka & Shukurov LLP is investigating potential securities violations and breach of fiduciary duty claims involving the board of directors of...
T1D Exchange Names New Board Members
December 11, 2018 07:45 ET
|
T1D Exchange
BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- T1D Exchange, a nonprofit, research organization dedicated to accelerating therapies and improving care for people affected by type 1 diabetes, today...
Neuralstem Added to the Russell Microcap® Index
June 26, 2017 08:32 ET
|
Neuralstem, Inc.
GERMANTOWN, Md., June 26, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that it has...
Neuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder
May 17, 2017 16:05 ET
|
Neuralstem, Inc.
GERMANTOWN, Md., May 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing next generation treatments for nervous system diseases, today announced it has...
Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update
May 10, 2017 16:05 ET
|
Neuralstem, Inc.
GERMANTOWN, Md., May 10, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing next generation treatments for nervous system diseases, reported its financial...
Neuralstem to Present at 29th Annual ROTH Conference
March 08, 2017 07:03 ET
|
Neuralstem, Inc.
GERMANTOWN, Md., March 08, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell...
Neuralstem Announces Publication of NSI-189 Preclinical Data in Journal of Cellular Physiology
February 28, 2017 07:03 ET
|
Neuralstem, Inc.
-NSI-189 Showed Durable Functional Recovery in a Rodent Model of Ischemic Stroke- -NSI-189 Promoted Synaptic Remodeling After Stroke- GERMANTOWN, Md., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Neuralstem,...
Neuralstem Announces Issuance of U.S. Patent Covering NSI-189
February 22, 2017 07:03 ET
|
Neuralstem, Inc.
GERMANTOWN, Md., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem...
Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder
February 16, 2017 07:02 ET
|
Neuralstem, Inc.
- Phase 2 Data Now Expected Ahead of Schedule in 3Q 2017 - GERMANTOWN, Md., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development...
Neuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Co., LTD.
December 12, 2016 07:38 ET
|
Neuralstem, Inc.
GERMANTOWN, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural...